What is Liraglutide 5MG, 10MG & 30MG

Liraglutide 5MG, 10MG & 30MG is a synthetic, long-acting Glucagon-Like Peptide-1 (GLP-1) receptor agonist studied in research for its effects on glycemic control, profound weight loss, and metabolic regulation. It is intended exclusively for research use.

Regarding its chemical identity, Liraglutide has a molecular formula of C172H265N43O51 and a molecular weight of 3751.2 g/mol. Its reported canonical sequence is Acylated human GLP-1 analogue. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Liraglutide.

Product for research use.

Mechanism of action of Liraglutide

Liraglutide binds to and activates the GLP-1 receptor. It stimulates glucose-dependent insulin secretion, inhibits inappropriate glucagon release, significantly delays gastric emptying, and acts on the hypothalamus to reduce appetite and induce satiety.

Pharmacokinetics and pharmacodynamics of Liraglutide

Native GLP-1 has a half-life of 2 minutes. Liraglutide is modified with a C16 fatty acid chain that binds to albumin in the bloodstream, shielding it from DPP-IV degradation and extending its plasma half-life to approximately 13 hours, allowing for once-daily dosing.

Scientific evidence on Liraglutide

The available evidence on Liraglutide is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Extensively documented in clinical science (as the active ingredient in Saxenda/Victoza). In research, it serves as a gold-standard baseline for studying incretin mimetics, obesity reversal, beta-cell preservation, and cardiovascular risk reduction in metabolic syndrome.

Liraglutide applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Liraglutide protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Liraglutide, so no trial schemes or quantities are specified.

The presentations of this product (5MG, 10MG & 30MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Liraglutide

As a general guideline for laboratory handling, lyophilized peptides such as Liraglutide are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 5MG, 10MG & 30MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Liraglutide Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Liraglutide security profile

The documented safety information in open sources for Liraglutide is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Associated with significant gastrointestinal side effects in laboratory models (nausea, vomiting, delayed gastric emptying). There are theoretical and observed risks of pancreatitis and a specific warning regarding thyroid C-cell tumors based on rodent models.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Liraglutide in a comparative context

Liraglutide is a first-generation daily GLP-1 agonist. Compared to native GLP-1, it is highly stable. Compared to newer molecules like Semaglutide or Tirzepatide, Liraglutide requires daily administration and generally produces slightly lower total weight loss percentages.

History and development of Liraglutide

Developed by Novo Nordisk as an antidiabetic medication, it revolutionized the treatment of Type 2 Diabetes by addressing both blood sugar and weight. Its success paved the way for the current era of peptide-based anti-obesity medications.